
Sign up to save your podcasts
Or


Can cell therapy revolutionize hearing loss treatment? In this follow-up discussion, Brian Culley, CEO of Lineage Cell Therapeutics, shares exciting updates on the ReSonance™ (ANP1) program, a pioneering preclinical study exploring auditory neuron cell transplantation. Culley explains how lab-grown auditory neurons are being delivered to the inner ear to potentially restore damaged auditory pathways—a groundbreaking approach that could even complement existing treatments.
For more information on the ReSonance program, visit the company's website here.
By This Week in Hearing5
11 ratings
Can cell therapy revolutionize hearing loss treatment? In this follow-up discussion, Brian Culley, CEO of Lineage Cell Therapeutics, shares exciting updates on the ReSonance™ (ANP1) program, a pioneering preclinical study exploring auditory neuron cell transplantation. Culley explains how lab-grown auditory neurons are being delivered to the inner ear to potentially restore damaged auditory pathways—a groundbreaking approach that could even complement existing treatments.
For more information on the ReSonance program, visit the company's website here.

38,478 Listeners

9,503 Listeners

30,270 Listeners

87,200 Listeners

112,454 Listeners

24,686 Listeners

8,434 Listeners

5,427 Listeners

20 Listeners

58,247 Listeners

165 Listeners

1,043 Listeners